Skip to content

Study · Animal study (in vivo) · rat · 1985

5 results

Growth hormone-releasing factor analogue (hGRF1-29NH2): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration.

Rafferty B, Poole S, Clarke R, Schulster D

The Journal of endocrinology1 Dec 1985Cited by 16 (Europe PMC)

PMID2866222 (opens in a new tab)DOI10.1677/joe.0.107r005 (opens in a new tab)PepBankPUB-02866222
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In anaesthetized rats, immunoreactive hGRF 1-29NH2 had an initial distribution half-life of 1.9 min after i.v. injection.

    In plain wordsIn rats, the peptide was cleared from the blood quickly at first, with a half-life of 1.9 minutes.

    Peptide
    Sermorelin
    Outcome
    Not applicableInitial distribution half-life (alpha) after i.v. injection
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 micrograms · intravenousAs given in this study (rat).

    Measurements

    half-life (alpha, distribution phase)
    1.9 min
    i.v. 10 micrograms

    Source sentences

    Summary
    Analysis of the biphasic disappearance curve of IR-hGRF-1-29NH2 from plasma after i.v. injection (10 micrograms) gave values for the half-lives of the initial distribution phase (alpha) and for the elimination phase (beta) of 1.9 +/- 0.2 min and 10.4 +/- 0.2 min respectively.
    1 context sentence
    Summary · context
    A homologous radioimmunoassay (RIA) system for human growth hormone-releasing factor 1-29NH2 (hGRF 1-29-NH2) was developed and applied to the measurement of immunoreactive (IR) concentrations of the peptide in anaesthetized rats to determine some of its pharmaco-kinetics after i.v. and s.c. administration.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In anaesthetized rats, immunoreactive hGRF 1-29NH2 had an elimination half-life of 10.4 min after i.v. injection.

    In plain wordsIn rats, the peptide had an elimination half-life in blood of 10.4 minutes.

    Peptide
    Sermorelin
    Outcome
    Not applicableElimination half-life (beta) after i.v. injection
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 micrograms · intravenousAs given in this study (rat).

    Measurements

    half-life (beta, elimination phase)
    10.4 min
    i.v. 10 micrograms

    Source sentences

    Summary
    Analysis of the biphasic disappearance curve of IR-hGRF-1-29NH2 from plasma after i.v. injection (10 micrograms) gave values for the half-lives of the initial distribution phase (alpha) and for the elimination phase (beta) of 1.9 +/- 0.2 min and 10.4 +/- 0.2 min respectively.
    1 context sentence
    Summary · context
    A homologous radioimmunoassay (RIA) system for human growth hormone-releasing factor 1-29NH2 (hGRF 1-29-NH2) was developed and applied to the measurement of immunoreactive (IR) concentrations of the peptide in anaesthetized rats to determine some of its pharmaco-kinetics after i.v. and s.c. administration.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In anaesthetized rats, the estimated total amount of immunoreactive hGRF1-29NH2 in the circulation after s.c. injection was only 4% of that after i.v. administration.

    In plain wordsIn rats, only 4% as much peptide reached the blood after an injection under the skin as after an injection into a vein.

    Peptide
    Sermorelin
    Outcome
    DecreaseCirculating amount after s.c. versus i.v. administration
    Study

    ratn: not reported in source

    Comparator
    Intravenous administration
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    relative circulating amount (AUC), s.c. versus i.v.
    4%
    rats

    Source sentences

    Summary
    comparison of areas under the plasma IR-hGRF1-29NH2/time curves showed that the estimated total amount in the circulation after s.c. injection was only 4% of that obtained after i.v. administration.
    1 context sentence
    Summary · context
    A homologous radioimmunoassay (RIA) system for human growth hormone-releasing factor 1-29NH2 (hGRF 1-29-NH2) was developed and applied to the measurement of immunoreactive (IR) concentrations of the peptide in anaesthetized rats to determine some of its pharmaco-kinetics after i.v. and s.c. administration.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In anaesthetized rats, the peptide was taken up rapidly from the subcutaneous injection site.

    In plain wordsIn rats, the peptide moved quickly from the injection site under the skin.

    Peptide
    Sermorelin
    Outcome
    Not applicableUptake from the s.c. injection site
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    There was rapid uptake of the peptide from the site of s.c. injection
    1 context sentence
    Summary · context
    A homologous radioimmunoassay (RIA) system for human growth hormone-releasing factor 1-29NH2 (hGRF 1-29-NH2) was developed and applied to the measurement of immunoreactive (IR) concentrations of the peptide in anaesthetized rats to determine some of its pharmaco-kinetics after i.v. and s.c. administration.

Studies that did not test the peptide alone1

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 05AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Other

    A homologous radioimmunoassay for hGRF 1-29NH2 was developed and used to measure its plasma concentrations in anaesthetized rats.

    In plain wordsIn rats, a new antibody-based test was built to measure this peptide in blood.

    Peptide
    Sermorelin
    Outcome
    Not applicableHomologous radioimmunoassay for hGRF 1-29NH2
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    A homologous radioimmunoassay (RIA) system for human growth hormone-releasing factor 1-29NH2 (hGRF 1-29-NH2) was developed and applied to the measurement of immunoreactive (IR) concentrations of the peptide in anaesthetized rats to determine some of its pharmaco-kinetics after i.v. and s.c. administration.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.